Drug Profile
ATG 037
Alternative Names: ATG-037; ATN-037; CB-708Latest Information Update: 24 Nov 2023
Price :
$50
*
At a glance
- Originator Calithera Biosciences
- Developer Antengene Corporation; Calithera Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action 5-nucleotidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies; Solid tumours
- Preclinical Multiple myeloma
Most Recent Events
- 17 Nov 2023 Efficacy data from the phase I STAMINA trial in Solid tumors released by Antengene Corporation
- 17 Apr 2023 Preclinical trials in Multiple myeloma in China (PO)
- 17 Apr 2023 Pharmacodynamics data from preclinical trial in Multiple myeloma presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)